During the recent session, BioXcel Therapeutics Inc (NASDAQ:BTAI)’s traded shares were 0.82 million, with the beta value of the company hitting 0.19. At the last check today, the stock’s price was $0.50, reflecting an intraday loss of -11.50% or -$0.07. The company’s market capitalization is $21.59M, and the average intraday trading volume over the past 10 days was 0.47 million shares, and the average trade volume was 485.61K shares over the past three months.
BioXcel Therapeutics Inc (BTAI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.50. BTAI has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.31.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information
BioXcel Therapeutics Inc (BTAI) registered a -11.50% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -11.50% in intraday trading to $0.50, hitting a weekly high. The stock’s 5-day price performance is -11.14%, and it has moved by -15.83% in 30 days. Based on these gigs, the overall price performance for the year is -86.81%. The short interest in BioXcel Therapeutics Inc (NASDAQ:BTAI) is 0.35 million shares and it means that shorts have 0.93 day(s) to cover.
The consensus price target of analysts on Wall Street is $10, which implies an increase of 95.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1 and $25 respectively. As a result, BTAI is trading at a discount of -4900.0% off the target high and -100.0% off the low.
BioXcel Therapeutics Inc (BTAI) estimates and forecasts
Statistics show that BioXcel Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. BioXcel Therapeutics Inc (BTAI) shares have gone down -72.85% during the last six months, with a year-to-date growth rate more than the industry average at 70.73% against 17.90. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 59.21% this quarter and then jump 48.28% in the quarter after that. In the rating firms’ projections, revenue will increase 67.67% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 413.84k as predicted by 2 analyst(s).
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -35.97%. While earnings are projected to return 72.40% in 2024.
BTAI Dividends
BioXcel Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
BioXcel Therapeutics Inc (NASDAQ:BTAI)’s Major holders
BioXcel Therapeutics Inc insiders own 20.06% of total outstanding shares while institutional holders control 8.76%, with the float percentage being 10.96%. ARMISTICE CAPITAL, LLC is the largest shareholder of the company, while 72.0 institutions own stock in it. As of 2024-06-30, the company held over 2.99 million shares (or 9.6767% of all shares), a total value of $3.82 million in shares.
The next largest institutional holding, with 2.21 million shares, is of FMR LLC’s that is approximately 7.1439% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.82 million.
Also, the Mutual Funds coming in first place with the largest holdings of BioXcel Therapeutics Inc (BTAI) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Jun 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 640.25 shares. This amounts to just over 1.50 percent of the company’s overall shares, with a $0.33 million market value. The same data shows that the other fund manager holds slightly less at 293.32, or about 0.69% of the stock, which is worth about $0.15 million.
